Experimental stroke

Kunlin Jin, Guo Yuan Yang

Research output: Book/ReportBook

Abstract

Stroke remains the third leading cause of death in the United States. Even among survivors, disability due to hemiparesis, gait disorders, aphasia and other deficits is common and about 20% of stroke survivors require institutional care at 6 months post-stroke. This long-term disability contributes to the average lifetime cost for stroke care of ~$140,000 and an annual national cost of ~$54 billion. The most recent major advance in clinical ischemic stroke treatment, the use of thrombolytic agents to dissolve clots in the acute aftermath of stroke, appears to be effective only within the first 3 hours after onset of symptoms; therefore, widely effective treatment for stroke remains elusive, and remains one of the biggest medical challenges in the 21st century.

Original languageEnglish
PublisherBentham Science Publishers B.V.
ISBN (Print)9781608056668
DOIs
StatePublished - 1 Dec 2008

Fingerprint

Stroke
Survivors
Costs and Cost Analysis
Fibrinolytic Agents
Aphasia
Paresis
Gait
Cause of Death
Therapeutics

Cite this

Jin, K., & Yang, G. Y. (2008). Experimental stroke. Bentham Science Publishers B.V. https://doi.org/10.2174/97816080500171090101
Jin, Kunlin ; Yang, Guo Yuan. / Experimental stroke. Bentham Science Publishers B.V., 2008.
@book{7cf84af70a3545ba811161a5fe4e6bcc,
title = "Experimental stroke",
abstract = "Stroke remains the third leading cause of death in the United States. Even among survivors, disability due to hemiparesis, gait disorders, aphasia and other deficits is common and about 20{\%} of stroke survivors require institutional care at 6 months post-stroke. This long-term disability contributes to the average lifetime cost for stroke care of ~$140,000 and an annual national cost of ~$54 billion. The most recent major advance in clinical ischemic stroke treatment, the use of thrombolytic agents to dissolve clots in the acute aftermath of stroke, appears to be effective only within the first 3 hours after onset of symptoms; therefore, widely effective treatment for stroke remains elusive, and remains one of the biggest medical challenges in the 21st century.",
author = "Kunlin Jin and Yang, {Guo Yuan}",
year = "2008",
month = "12",
day = "1",
doi = "10.2174/97816080500171090101",
language = "English",
isbn = "9781608056668",
publisher = "Bentham Science Publishers B.V.",

}

Jin, K & Yang, GY 2008, Experimental stroke. Bentham Science Publishers B.V. https://doi.org/10.2174/97816080500171090101

Experimental stroke. / Jin, Kunlin; Yang, Guo Yuan.

Bentham Science Publishers B.V., 2008.

Research output: Book/ReportBook

TY - BOOK

T1 - Experimental stroke

AU - Jin, Kunlin

AU - Yang, Guo Yuan

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Stroke remains the third leading cause of death in the United States. Even among survivors, disability due to hemiparesis, gait disorders, aphasia and other deficits is common and about 20% of stroke survivors require institutional care at 6 months post-stroke. This long-term disability contributes to the average lifetime cost for stroke care of ~$140,000 and an annual national cost of ~$54 billion. The most recent major advance in clinical ischemic stroke treatment, the use of thrombolytic agents to dissolve clots in the acute aftermath of stroke, appears to be effective only within the first 3 hours after onset of symptoms; therefore, widely effective treatment for stroke remains elusive, and remains one of the biggest medical challenges in the 21st century.

AB - Stroke remains the third leading cause of death in the United States. Even among survivors, disability due to hemiparesis, gait disorders, aphasia and other deficits is common and about 20% of stroke survivors require institutional care at 6 months post-stroke. This long-term disability contributes to the average lifetime cost for stroke care of ~$140,000 and an annual national cost of ~$54 billion. The most recent major advance in clinical ischemic stroke treatment, the use of thrombolytic agents to dissolve clots in the acute aftermath of stroke, appears to be effective only within the first 3 hours after onset of symptoms; therefore, widely effective treatment for stroke remains elusive, and remains one of the biggest medical challenges in the 21st century.

UR - http://www.scopus.com/inward/record.url?scp=84891581012&partnerID=8YFLogxK

U2 - 10.2174/97816080500171090101

DO - 10.2174/97816080500171090101

M3 - Book

AN - SCOPUS:84891581012

SN - 9781608056668

BT - Experimental stroke

PB - Bentham Science Publishers B.V.

ER -

Jin K, Yang GY. Experimental stroke. Bentham Science Publishers B.V., 2008. https://doi.org/10.2174/97816080500171090101